BACM
VNDA icon

Blue Arrow Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Blue Arrow Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-160,000
Closed -$1.49M – 184
2015
Q1 		$1.49M Buy
+160,000
New +$1.81M 0.15% 113

Other funds holding VNDA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Blue Arrow Capital Management's VNDA Position: Q2 2015 in Review

Blue Arrow Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2015, closing a stake of 160,000 shares — an estimated $1.49M sold.

Blue Arrow Capital Management first reported a position in VNDA in Q1 2015 and held it in 1 quarter. The position peaked at $1.49M in Q1 2015. 109 funds tracked by Wall St. Rank hold VNDA as of Q2 2015.

  • Blue Arrow Capital Management reported no remaining Vanda Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 160,000 Vanda Pharmaceuticals shares in Q2 2015, an estimated $1.49M.
  • Blue Arrow Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Blue Arrow Capital Management's Vanda Pharmaceuticals position peaked at $1.49M in Q1 2015.
  • 109 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2015.

Based on Blue Arrow Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.